Literature DB >> 11574606

Comparative performance of herpes simplex virus type 2-specific serologic assays from Meridian Diagnostics and MRL diagnostics.

J A Ribes1, M Hayes, A Smith, J L Winters, D J Baker.   

Abstract

MRL Diagnostics and Meridian Diagnostics have recently designed herpes simplex virus type 2 (HSV-2)-specific enzyme immunoassays for HSV-2 antibody detection. Blood donor sera were assayed for HSV-2 antibodies by both methods. The sensitivity, specificity, and efficiency were 97.9, 95.4, and 95.9% for the MRL assay and 83.2, 98.2, and 95.5% for the Meridian assay, respectively.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11574606      PMCID： PMC88422          DOI： 10.1128/JCM.39.10.3740-3742.2001

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  14 in total

1.  Rapid identification and typing of herpes simplex virus types 1 and 2 by a direct immunofluorescence technique.

Authors:  A Nahmias; I DelBuono; J Pipkin; R Hutton; C Wickliffe
Journal:  Appl Microbiol       Date:  1971-09

Review 2.  Antigenic and biologic differences in herpesvirus hominis.

Authors:  A J Nahmias; W R Dowdle
Journal:  Prog Med Virol       Date:  1968

3.  Herpes simplex virus type 2 detection by culture and polymerase chain reaction and relationship to genital symptoms and cervical antibody status during the third trimester of pregnancy.

Authors:  K A Boggess; D H Watts; A C Hobson; R L Ashley; Z A Brown; L Corey
Journal:  Am J Obstet Gynecol       Date:  1997-02       Impact factor: 8.661

4.  Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention.

Authors: 
Journal:  MMWR Recomm Rep       Date:  1998-10-16

5.  Role of type specific herpes simplex virus serology in the diagnosis and management of genital herpes.

Authors:  P E Munday; J Vuddamalay; M J Slomka; D W Brown
Journal:  Sex Transm Infect       Date:  1998-06       Impact factor: 3.519

6.  Herpes simplex virus shedding among human immunodeficiency virus-negative men who have sex with men: site and frequency of shedding.

Authors:  M R Krone; S R Tabet; M Paradise; A Wald; L Corey; C L Celum
Journal:  J Infect Dis       Date:  1998-10       Impact factor: 5.226

Review 7.  Genital herpes simplex virus infections: current concepts in diagnosis, therapy, and prevention.

Authors:  L Corey; K K Holmes
Journal:  Ann Intern Med       Date:  1983-06       Impact factor: 25.391

8.  Determination of herpes simplex virus type-specific antibodies by enzyme-linked immunosorbent assay.

Authors:  R M Coleman; L Pereira; P D Bailey; D Dondero; C Wickliffe; A J Nahmias
Journal:  J Clin Microbiol       Date:  1983-08       Impact factor: 5.948

9.  Antibodies to Herpesvirus hominis types 1 and 2 in humans. I. Patients with genital herpetic infections.

Authors:  A J Nahmias; W E Josey; Z M Naib; C F Luce; A Duffey
Journal:  Am J Epidemiol       Date:  1970-06       Impact factor: 4.897

10.  Risk of recurrence after first episodes of genital herpes. Relation to HSV type and antibody response.

Authors:  W C Reeves; L Corey; H G Adams; L A Vontver; K K Holmes
Journal:  N Engl J Med       Date:  1981-08-06       Impact factor: 91.245
View more
  13 in total

1.  Comparative performance of herpes simplex virus type 1-specific serologic assays from MRL and Meridian Diagnostics.

Authors:  Julie A Ribes; Angela Smith; Marie Hayes; Doris J Baker; Jeffrey L Winters
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

2.  Plasma versus serum for detection of herpes simplex virus type 2-specific immunoglobulin G antibodies with a glycoprotein G2-based enzyme immunoassay.

Authors:  Thomas L Cherpes; Leslie A Meyn; Sharon L Hillier
Journal:  J Clin Microbiol       Date:  2003-06       Impact factor: 5.948

3.  Longitudinal reliability of focus glycoprotein G-based type-specific enzyme immunoassays for detection of herpes simplex virus types 1 and 2 in women.

Authors:  Thomas L Cherpes; Rhoda L Ashley; Leslie A Meyn; Sharon L Hillier
Journal:  J Clin Microbiol       Date:  2003-02       Impact factor: 5.948

4.  Comparison of commercial methods of immunoblot, ELISA, and chemiluminescent immunoassay for detecting type-specific herpes simplex viruses-1 and -2 IgG.

Authors:  Fernando de Ory; María-Eulalia Guisasola; Pilar Balfagón; Juan Carlos Sanz
Journal:  J Clin Lab Anal       Date:  2017-03-23       Impact factor: 2.352

5.  Production of a fragment of glycoprotein G of herpes simplex virus type 2 and evaluation of its diagnostic potential.

Authors:  Tao Liu; Ji Feng Liu; Hua Yu; Guo Jing Si; Jun Hu; Jun Li
Journal:  Singapore Med J       Date:  2015-06       Impact factor: 1.858

6.  Serologic detection of herpes simplex virus type 2 antibodies among pregnant women using a point-of-care test from Focus Diagnostics.

Authors:  Bridget Leyland; Margaret R Kennedy; Yolanda H Wimberly; Bruce J Levine; Thomas L Cherpes
Journal:  J Clin Virol       Date:  2009-01-07       Impact factor: 3.168

7.  Regional distribution of antibodies to herpes simplex virus type 1 (HSV-1) and HSV-2 in men and women in Ontario, Canada.

Authors:  Michelle Howard; John W Sellors; Dan Jang; Noah J Robinson; Margaret Fearon; Janusz Kaczorowski; Max Chernesky
Journal:  J Clin Microbiol       Date:  2003-01       Impact factor: 5.948

8.  Detection of herpes simplex virus type 2-specific immunoglobulin G antibodies in African sera by using recombinant gG2, Western blotting, and gG2 inhibition.

Authors:  Wayne Hogrefe; Xin Su; James Song; Rhoda Ashley; Lilly Kong
Journal:  J Clin Microbiol       Date:  2002-10       Impact factor: 5.948

9.  Adolescent Sexually Transmitted Diseases: Recent Developments.

Authors:  Diane R. Blake
Journal:  Curr Infect Dis Rep       Date:  2004-04       Impact factor: 3.725

Review 10.  Light microscopy, culture, molecular, and serologic methods for detection of herpes simplex virus.

Authors:  Neil W Anderson; Blake W Buchan; Nathan A Ledeboer
Journal:  J Clin Microbiol       Date:  2013-10-16       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.